AAV-CNGB1 gene therapy (Sanofi/Ludwig Maximilians-Universitat Munchen)

N/A

Report date: 2025/03/14 16:46:50

Base Information

Drug NameAAV-CNGB1 gene therapy (Sanofi/Ludwig Maximilians-Universitat Munchen)
Drug Alias NamerAAV.CNGB1recombinant adeno-associated virus based hCNGB1 gene therapy (Sanofi/Ludwig Maximilians-Universitat Munchen)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionCyclic nucleotide-gated channel alpha-1 stimulants
TargetsCyclic nucleotide-gated channel alpha-1
Therapy Area/IndicationsRetinitis Pigmentosa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesLudwig-Maximilians-Universität MünchenGenzyme Corp
Inactive CompaniesN/A
Active IndicationsRetinitis Pigmentosa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A